High	O
-	O
grade	O
clear	B-Cancer
cell	I-Cancer
renal	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
has	O
a	O
higher	O
angiogenic	O
activity	O
than	O
low	O
-	O
grade	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
based	O
on	O
histomorphological	O
quantification	O
and	O
qRT	O
-	O
PCR	O
mRNA	O
expression	O
profile	O
.	O

Clear	B-Cancer
cell	I-Cancer
renal	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
(	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
)	O
is	O
a	O
highly	O
vascularised	O
tumour	B-Cancer
and	O
is	O
therefore	O
an	O
attractive	O
disease	O
to	O
study	O
angiogenesis	O
and	O
to	O
test	O
novel	O
angiogenesis	O
inhibitors	O
in	O
early	O
clinical	O
development	O
.	O

Endothelial	B-Cell
cell	I-Cell
proliferation	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
of	O
angiogenesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
angiogenesis	O
parameters	O
in	O
low	O
nuclear	B-Cellular_component
grade	O
(	O
n	O
=	O
87	O
)	O
vs	O
high	O
nuclear	B-Cellular_component
grade	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
(	O
n	O
=	O
63	O
)	O
.	O

A	O
panel	O
of	O
antibodies	O
was	O
used	O
for	O
immunohistochemistry	O
:	O
CD34	O
/	O
Ki	O
-	O
67	O
,	O
carbonic	O
anhydrase	O
IX	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

Vessel	B-Multi-tissue_structure
density	O
(	O
MVD	O
-	O
microvessel	B-Tissue
density	O
)	O
,	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
fraction	O
(	O
ECP	O
%	O
)	O
and	O
tumour	B-Cell
cell	I-Cell
proliferation	O
fraction	O
(	O
TCP	O
%	O
)	O
were	O
assessed	O
.	O

mRNA	O
expression	O
levels	O
of	O
angiogenesis	O
stimulators	O
and	O
inhibitors	O
were	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

High	O
-	O
grade	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
showed	O
a	O
higher	O
ECP	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
)	O
,	O
a	O
higher	O
TCP	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
higher	O
VEGF	O
protein	O
expression	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
a	O
lower	O
MVD	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
a	O
lower	O
HIF	O
-	O
1alpha	O
protein	O
expression	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
low	O
-	O
grade	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
.	O

Growth	O
factor	O
mRNA	O
expression	O
analyses	O
revealed	O
a	O
higher	O
expression	O
of	O
angiopoietin	O
2	O
in	O
low	O
-	O
grade	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
.	O

Microvessel	B-Tissue
density	O
and	O
ECP	O
%	O
were	O
inversely	O
correlated	O
(	O
Rho	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Because	O
of	O
the	O
imperfect	O
association	O
of	O
nuclear	B-Cellular_component
grade	O
and	O
ECP	O
%	O
or	O
MVD	O
,	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
was	O
also	O
grouped	O
based	O
on	O
low	O
/	O
high	O
MVD	O
and	O
ECP	O
%	O
.	O

This	O
analysis	O
revealed	O
a	O
higher	O
expression	O
of	O
vessel	B-Multi-tissue_structure
maturation	O
and	O
stabilisation	O
factors	O
(	O
placental	O
growth	O
factor	O
,	O
PDGFB1	O
,	O
angiopoietin	O
1	O
)	O
in	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
with	O
high	O
MVD	O
,	O
a	O
group	O
of	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
highly	O
enriched	O
in	O
low	O
nuclear	B-Cellular_component
grade	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
,	O
with	O
low	O
ECP	O
%	O
.	O

Our	O
results	O
suggest	O
heterogeneity	O
in	O
angiogenic	O
activity	O
and	O
vessel	B-Multi-tissue_structure
maturation	O
of	O
CC	B-Cancer
-	I-Cancer
RCC	I-Cancer
,	O
to	O
a	O
large	O
extent	O
linked	O
to	O
nuclear	B-Cellular_component
grade	O
,	O
and	O
,	O
with	O
probable	O
therapeutic	O
implications	O
.	O

